EU/3/19/2215

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2215 was granted by the European Commission to Boyd Consultants Limited, Ireland, for paclitaxel for the treatment of soft tissue sarcoma.

Key facts

Active substance
paclitaxel
Disease / condition
Treatment of soft tissue sarcoma
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2215

Sponsor's contact details

Boyd Consultants Limited 
Dublin City University
DCU Invent
Glasnevin Dublin 9
Ireland 
E-mail: regulatory@boydconsultants.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating